Latest News

Expanesthetics Works With Assemblymembers to Support AB 593

February 16, 2021 | Sacramento Business Journal

California lawmakers introduced a bill Tuesday aimed at restoring tax credits for life science companies. The “Golden State Innovation Act of 2021" seeks to bring back a research and development tax credit that was suspended in the 2019-2020 budget year when lawmakers were looking to close a budget deficit projected because of the pandemic. The bill, introduced as Assembly Bill 593, would also restore a net operating loss deduction for life sciences companies. Health care and life science-focused companies lined up in support of the new bill, including Davis-based Expanesthetics Inc.

Back to top

Expanesthetics enters research agreement with NIH

December 2, 2020 | Expanesthetics.com

Expanesthetics, Inc. today announced that it has entered into a research agreement with the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), USA. In order to maintain scientific integrity, the terms of the agreement are not being publicly disclosed by Expanesthetics.

Back to top

Davis-based pharmaceutical company looks to raise $15.7 million

October 27, 2020 | Sacramento Business Journal

Davis-based Expanesthetics Inc. is looking to raise funds to fuel its research into anesthetics. Expanesthetics develops new inhaled general anesthetics with fewer side effects and pain relievers that serve as alternatives to opioids.

EDITOR'S NOTE: This article contains a few inaccuracies, including an implication that Expanesthetics' new general anesthetics are novel in their ability to be inhaled. Inhaled general anesthetics are already widely available—the agents Expanesthetics is developing are novel because of their more specific mechanisms of action compared to conventional agents, with the intent of causing fewer side effects.

Back to top

Expanesthetics Launches $16 Million Offering

October 1, 2020 | Expanesthetics.com

Expanesthetics launched a new offering budgeted to power the company’s anesthetic screening program through first-in-human trials of a lead anesthetic candidate, as well as research in the company’s non-opiate pain reliever program. The company has previously raised over $7.5 million, primarily from nearly 100 anesthesia clinicians. The investment includes stock shares as well as warrants to buy more stock later at the current price. Expanesthetics’ anesthetic program aims to develop new inhaled general anesthetics with fewer side effects than agents available today. The company’s exclusive technology allows it to identify new anesthetic candidates that affect fewer receptors in the central nervous system. This more specific mechanism of action enables drug candidates with fewer side effects, which has been supported by the company’s proof-of-concept research. Click the headline to learn more about the investment offering

Back to top

Davis-based company raises funds to research alternatives to opioids

March 6, 2019 | Sacramento Business Journal

See article for full text.

EDITOR'S NOTE: This article contains several inaccuracies but highlights the end of two capital raising initiatives the company recently completed. Importantly, none of our funding has come from venture capital firms as stated in the first sentence of the article. Additionally, while the company continues to aim to raise a large bolus of capital in two stages to fund the development of our anesthetic program, the figure described in the article is no longer up to date.

Back to top